Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
Brain Imaging Behav. Author manuscript; available in PMC 2012 December 29.
Published in final edited form as:
PMCID: PMC3532521

Longitudinal change in neuropsychological performance using latent growth models: a study of mild cognitive impairment

Julene K. Johnson,corresponding author Alden L. Gross, Judy Pa, Donald G. McLaren, Lovingly Quitania Park, Jennifer J. Manly, and for the Alzheimer's Disease Neuroimaging Initiative


The goal of the current study was to examine cognitive change in both healthy controls (n=229) and individuals with mild cognitive impairment (MCI) (n=397) from the Alzheimer's Disease Neuroimaging Initiative (ADNI). We applied latent growth modeling to examine baseline and longitudinal change over 36 months in five cognitive factors derived from the ADNI neuropsychological test battery (memory, executive function/processing speed, language, attention and visuospatial). At baseline, MCI patients demonstrated lower performance on all of the five cognitive factors when compared to controls. Both controls and MCI patients declined on memory over 36 months; however, the MCI patients declined at a significantly faster rate than controls. The MCI patients also declined over 36 months on the remaining four cognitive factors. In contrast, the controls did not exhibit significant change over 36 months on the non-memory cognitive factors. Within the MCI group, executive function declined faster than memory, while the other factor scores changed slower than memory over time. These findings suggest different patterns of cognitive change in healthy older adults and MCI patients. The findings also suggest that, when compared with memory, executive function declines faster than other cognitive factors in patients with MCI. Thus, decline in non-memory domains may be an important feature for distinguishing healthy older adults and persons with MCI.

Keywords: ADNI, Neuropsychology, Cognition, Mild cognitive impairment, Cognitive change, Executive function


Neuropsychological assessment is an important component for the differential diagnosis of cognitive decline associated with neurodegenerative diseases, such as Alzheimer's disease and dementia with Lewy bodies. It can also be used to help identify subtle cognitive change associated with mild cognitive impairment (MCI), an intermediate stage between healthy aging and dementia (Petersen, Smith 1999; Winblad et al. 2004). However, a major challenge lies in distinguishing normal age-related cognitive decline from cognitive decline due to an underlying neurodegenerative disease, particularly because the neuropathology can begin decades before the onset of overt cognitive impairment (Albert et al. 2011; Morris et al. 2001). The administration of a comprehensive neuropsychological battery over time (e.g., annually) that assesses multiple cognitive domains is one strategy used to increase confidence in the diagnosis (Dowling et al. 2010). While approximately half of all MCI patients convert to dementia over 5 years, other MCI patients remain stable or revert to normal (Bennett et al. 2002; Manly et al. 2008; Petersen et al. 2001). Thus, it is important to better understand how cognition changes over time in both healthy older adults and those with MCI to help improve the early detection of neurodegenerative diseases.

There are a number of analytic methods to study cognitive change in longitudinal data, including application of repeated measures analysis of variance (ANOVA), mixed effects models (Laird and Ware 1982), and differences in means (Twisk 2003). Latent growth modeling is another method for analyzing longitudinal data to estimate growth, or trajectories of change (McArdle 1986; Muthén 1997; Muthén and Curran 1997). There are several advantages to using this method to study cognitive decline. First, latent growth models provide estimates of individual trajectories of change. In the context of structural equation modeling, they offer flexible extensions, such as the ability to model change in latent outcomes that represent common variation in multiple observed indicators (McArdle 1988; Stoel et al. 2003). Secondly, the models can help identify common constructs within neuropsychological test batteries, which often use multiple tests to measure several cognitive domains and generate a large number of test scores. For example, the Rey Auditory Verbal Learning Test, a common test of verbal list learning and memory, can yield multiple individual trial scores, a learning score, short- and long-delay recall scores, and recognition scores. As such, it can be challenging to select an optimal neuropsychological variable to represent a specific cognitive domain. Using multiple variables increases the Type I error rate, but controlling for multiple comparisons increases the risk of Type II errors. Thus, in addition to identifying common constructs, latent growth models help avoid these pitfalls through a principled data reduction method.

The goal of the current study was to apply latent growth models to examine cognitive change in both healthy controls and individuals with MCI. To accomplish this goal, we utilized data from the Alzheimer's Disease Neuroimaging Initiative (ADNI). Using five cognitive factors representing memory, executive function/processing speed, visuospatial ability, language, and attention (Park et al., this issue), we hypothesized that cognition (represented by factor scores) declines faster over time in individuals with MCI compared with healthy controls. Additionally, we hypothesized that there would be an interaction between change in cognitive factors and group, such that memory would decline faster than other cognitive domains in MCI patients. These hypotheses were assessed using latent growth models.


The Alzheimer's disease neuroimaging initiative

The ADNI is a private-public partnership launched in 2003 (Weiner et al. 2011) to develop optimized methods for acquiring longitudinal, multisite neuroimaging and chemical biomarkers, clinical, cognitive, and biomarker data in a large cohort of patients with AD, patients with MCI, and healthy controls to improve methods for evaluating progression in clinical trials. More than 800 participants, ages 55–90 years, have been recruited from 59 sites across the United States and Canada. The data used for the present study, which are freely available to subscribers and continuously updated, were downloaded on March 15, 2011.


The present study included data from ADNI participants who were diagnosed at baseline as healthy controls (n=229) and MCI patients (n=397). The criteria for a diagnosis of MCI (Petersen et al. 2010) included: (i) age between 55 and 90 years; (ii) complaints of memory loss by the patient and confirmed by a family relative; (iii) Mini-Mental State Examination (MMSE; (Folstein et al. 1975) score greater than 23, (iv) Clinical Dementia Rating (CDR; (Morris 1993)) score of 0.5; and (v) evidence of memory impairment relative to age and education-matched peers on neuropsychological tests. Criteria for healthy controls included: (i) no memory complaints aside from those common to other normal subjects of that age range; (ii) normal memory function documented by scoring at specific cut offs on the Logical Memory II subscale from the Wechsler Memory Scale-Revised (Wechsler 1987b); (iii) MMSE score between 24 and 30 (inclusive); (iv) CDR score=0 and CDR memory box score=0; (v) clinical impression of cognitively normal, based on an absence of significant impairment in cognitive function or activities of daily living.

ADNI neuropsychological battery

For the present study, we included data from five ADNI study visits: baseline, 6 months, 12 months, 24 months, and 36 months. The ADNI neuropsychological battery includes tests that represent multiple cognitive domains (Petersen et al. 2010). Details about the administration and scoring are available at Briefly, episodic memory is assessed using the Rey Auditory Verbal Learning test (AVLT) (Rey 1964), which includes 5 learning trials (of 15 words), immediate and 30-minute delayed recall, as well as an interference list and recognition test. Tests of executive function and attention include: Digit Span (Wechsler 1987a), the Trailmaking test A and B (Reitan 1958), and the Digit Symbol Substitution Test (Wechsler 1981). Verbal fluency is assessed using tests of category fluency (Morris et al. 1989), and object naming is assessed using the Boston Naming Test (Kaplan et al. 1982). In addition to these tests, the Alzheimer's Disease Assessment Scale – Cognitive subscale (ADAS-Cog) (Rosen et al. 1984), MMSE, and the Clock Drawing Test (Goodglass and Kaplan 1983) are administered.

Factor structure of ADNI neuropsychological battery

As described in Park and colleagues (this issue), a factor analysis of the ADNI neuropsychological battery yielded five factors: memory, executive function/processing speed, visuospatial ability, language, and attention. The memory factor is represented by: AVLT, including learning (Trial 5 minus Trial 1), immediate recall, 30-minute delayed recall, and recognition scores, and the ADAS-Cog delayed recall and recognition. A factor representing executive function and processing speed is composed of: Trailmaking Test A (time to complete), Trailmaking Test (B minus A), number cancellation (number completed in 60 s), and the Digit Symbol Substitution Test (number completed in 90 s). Visuospatial ability is represented by: Clock Drawing Test (copy and drawing scores) and ADAS-Cog constructional praxis (number correct). Language is represented by: category fluency (animals and vegetables in 1 min), the Boston Naming Test (number of items spontaneously named), and ADAS-Cog Naming (number correct). Attention is represented by: the Digit Span (forward and backward span length).

To place parameters of interest on an interpretable scale and to compare relative change within and between cognitive domains, all neuropsychological test variables used in this study were standardized as T-scores [mean 50, standard deviation (SD) 10] at the baseline. Follow-up visits were similarly rescaled using the baseline mean and SD to preserve longitudinal change. Importantly, this scaling procedure facilitates comparisons within the present study sample, but absolute values of parameter scores are not generalizable to other studies.


Longitudinal change in cognitive domains was assessed using a multiple indicator latent growth model with the latent variables derived from a previously validated factor analysis of the baseline ADNI neuropsychological battery (Park et al., this issue). Multiple indicator parallel process latent growth models were used to model domain-specific cognitive trajectories (see Fig. 1 for a model diagram). These are multiple indicator growth models because several observed indicators were used to define latent variables at each time point, which served as indicators for growth. The models are parallel process models because two growth processes (memory and another domain) were estimated together. A separate model was estimated for visuospatial, language, executive function/processing speed, and attention constructs. The memory growth process was part of each model to compare level and change in that domain with others. Parameters of interest are means of growth parameters, which included intercepts (initial status indicators) and slopes (linear trajectories). Observed indicator scores were all rescaled on a T-score metric. Therefore, a latent intercept is interpretable as the mean performance at baseline relative to the mean in the full MCI and healthy control sample. Slopes represent changes in T-score units per year. Two sample t-tests were conducted to test group differences in the intercepts and slopes of each model.

Fig. 1
Model Diagram of a Multiple Indicator Parallel Process Latent Growth Model for the ADNI Neuropsychological Test Battery. This figure shows the parameterization of the model of growth processes for memory and other cognitive domain (executive function, ...

Constraints imposed are consistent with strict temporal invariance, which is consistent with a factor structure not changing over the course of disease (Park et al., this issue). Specifically, factor loadings of indicators on constructs at each study visit were constrained to be equal across time points. Residual variances of the latent constructs are constrained to be equal. Temporal correlations were permitted between like indicators at one visit and the following visit (Fig. 1). Methods correlations are correlations among items from the same test that may not represent meaningful variance of a construct (Garner et al. 1956; Strauss et al. 2000). For our study, methods correlations were also included for items from similar tests within a visit to model residual correlations and better represent observed data (e.g., AVLT items; see Fig. 1).

Statistical analyses were conducted using Mplus statistical software, version 6.11 (Muthén and Muthén 1998–2010). Model fit was evaluated using the root mean square error of approximation (RMSEA; (Steiger 1989)) and comparative fit index (CFI; (Hu and Bentler 1999)). An RMSEA below 0.05 and CFI above 0.90 are generally considered indicators of good model fit (Hu and Bentler 1999).


Baseline demographics and neuropsychological performance

Demographic information and group results on the neuropsychological tests are summarized in Table 1. The controls were slightly older than the MCI patients (76 versus 74 years) (p=0.04), and there was a higher percentage of males in the MCI group (p<0.01). There were no group differences in years of education. The ethnic composition of the sample was largely homogenous with a large percentage of subjects being white in both groups. As expected, participants with MCI scored worse than controls on all neuropsychological tests (all p<0.001).

Table 1
Baseline demographic characteristics and performance on individual tests

Latent growth modeling

Results of four multiple indicator parallel process models are shown in Table 2 and graphically in Fig. 2. The following results are described according to cognitive domain. Model fits were excellent (all RMSEA<=0.06; all CFI>0.86; Table 2). For all cognitive domains, initial recall parameter variances were considerably larger than indicator residual variances, suggesting more between-person heterogeneity in cognitive performance than within-person variability.

Fig. 2
Model-estimated trajectories of performance in cognitive factors by diagnostic status: Results from healthy control and MCI groups (n=626)
Table 2
Model parameter estimates summarizing growth processes in five neuropsychological factors by diagnostic status: Results from ADNI (n=626)

Memory factor

At baseline, the MCI patients performed approximately 1 SD below that of the healthy controls on memory, and this difference was statistically significant (p<0.001; Table 2 and Fig. 2). Both groups declined in memory performance over 36 months. However, the MCI patients declined in memory at approximately twice the rate of healthy control participants. Differences in the annual trajectories were statistically significant (p<0.001).

Executive function/processing speed factor

Similar to the memory results, the MCI group's baseline performance on executive function/processing speed was significantly lower than healthy controls (p<0.001). The MCI patients declined by 1.6 SD per year in executive function/processing speed (p<0.001), while there was no decline in executive function/processing speed by healthy controls (p=0.76). The trajectory of decline in MCI patients was significantly different than healthy controls (p<0.001).

Visuospatial factor

The results on the visuospatial factor are similar to executive function. MCI performance on the visuospatial factor was significantly lower than controls at baseline (p<0.001). Again only the MCI patients declined significantly in visuospatial performance, and this trajectory was significantly different from healthy controls (p<0.001).

Language factor

The MCI patients scored significantly lower than controls on the baseline language factor (p<0.001). Again, only the MCI patients declined on the language factor (p<0.001), while healthy controls did not decline (p=0.48). This difference was statistically significant (p<0.001).

Attention factor

The MCI patients scored significantly lower than controls on the baseline attention factor (p<0.001). Only the MCI patients showed significant annual decline, and this decline was significantly different than in healthy controls (p<0.001).

Diagnostic group by cognitive domain interactions

To better understand how domain-specific cognitive functions decline relative to each other, we compared the magnitudes of initial level and decline in each domain contrasted with memory within each diagnostic group. Differences in parameter intercepts and trajectories by diagnostic group are shown in Table 2 under Within-diagnostic group, between-domain differences. When considering the levels of baseline factor scores (i.e., parameter intercepts) in healthy controls, the baseline memory factor scores were significantly higher than the other non-memory cognitive factor scores (all p<0.001). In contrast, the baseline memory factor scores for the MCI patients were significantly lower than the other non-memory cognitive domains (all p<0.001). These baseline patterns were significantly different between groups, suggesting a diagnosis by cognitive domain interaction.

In terms of trajectory over time, among the MCI patients, executive function/processing speed declined 0.5 SD faster than memory (p<0.05). Other domains (visuospatial, language and attention) for MCI patients declined at a similar rate with memory (all p values>0.29). Thus, among MCI patients, decline in executive function/processing speed was faster than in memory and other cognitive factors. In contrast, executive function/processing speed, language, and attention factors declined significantly slower than the memory factor in controls. Table 2 shows significant differences in declines in executive function/processing speed, language, and attention factors relative to memory between controls and MCI. In summary, these results indicate at both baseline and over time that there are interactions between diagnostic group and cognitive domains, demonstrating interactions between diagnostic group and domain-specific cognitive decline.


Overall, the present study used latent growth modeling to examine baseline and longitudinal change in five cognitive factor scores derived from the ADNI neuropsychological battery in healthy controls and MCI patients. At baseline, compared with controls, MCI patients demonstrated lower performance on all of the five cognitive factors (memory, executive function/processing speed, language, attention and visuospatial). Both controls and MCI patients declined on memory over 36 months; however, the MCI patients declined at a significantly faster rate than controls on memory. The MCI patients also declined over 36 months on the remaining four cognitive factors (i.e., executive function/processing speed, language, attention and visuospatial). In contrast, the controls did not exhibit change on any of these non-memory cognitive factors over 36 months, which differed significantly from the MCI patients. Within the MCI group, executive function declined faster than memory, while the other factor scores changed at the same rate as memory over time. The results also suggest that executive function/processing speed declines faster than other cognitive factors, including memory, in patients with MCI. Thus, these findings suggest different patterns of cognitive decline in healthy older adults and MCI patients both at baseline and over time (e.g. diagnostic group by cognitive domain interactions).

As expected, MCI patients had lower performance on tests of memory at baseline in the ADNI study. As discussed above, the inclusion criteria for the ADNI study require that MCI patients have impaired memory and controls have intact memory performance. It is also not surprising that the MCI patients had lower baseline factors scores than controls on the other cognitive domains, as several studies suggest that MCI patients have deficits in non-memory domains relative to healthy controls (Hodges et al. 2006; Kramer et al. 2006; Matsuda and Saito 2009). An international work group outlined criteria for both single- and multiple-domain amnestic MCI (Winblad et al. 2004), and it is likely that the MCI patients in the ADNI study are classified as multiple-domain amnestic MCI rather than single-domain MCI according to this classification. Indeed, the memory cut-off on the Logical Memory subtest used for inclusion in ADNI is conservative, which likely identified MCI patients who are more impaired than the average MCI patient and have deficits in multiple cognitive domains. Thus, the baseline results in the current study are consistent with other studies suggesting that MCI patients often have deficits in multiple cognitive domains.

When considering change in cognitive performance over 36 months, the results from the latent growth models suggest that memory declined in both MCI patients and healthy controls. However, the rate of memory decline was different, with the MCI patients declining faster than controls. These results confirm other studies that document age-related memory decline in healthy older adults (Albert et al. 1995; Hayden et al. 2011; Wilson et al. 2002) and also other studies that document a steeper slope of memory decline in MCI patients compared with healthy controls (Bennett et al. 2002; Mungas et al. 2010). One recent study using random effects regression analysis reported that a majority (65 %) of healthy older adults declined at approximately 0.04 SD annually (equivalent to 0.4 factor units in the present study) on a global cognitive composite score (Hayden et al. 2011). Thus, the current findings about memory decline in both MCI and controls derived from the latent growth models are consistent with most studies using different methods and approaches.

The novel finding of the current study is that, while memory declined in both MCI and healthy controls, only MCI patients declined significantly on the other four non-memory cognitive factors (i.e., executive function/processing speed, language, visuospatial, and attention). This finding suggests that decline in non-memory domains may be an important feature for distinguishing healthy older adults and persons with MCI. That is, monitoring decline on non-memory domains may be more predictive of clinical progression than a decline in memory. A recent paper by Gomar and colleagues (Gomar et al. 2011), also using ADNI data, found that the change on the Trailmaking test B was a better indicator of conversion to Alzheimer's disease than change in memory. Although Carter and colleagues (Carter et al. 2011) argue that deficits in semantic cognition appear before executive dysfunction in MCI patients, several other authors have proposed that executive dysfunction is the second cognitive domain to be affected in MCI patients who progress clinically (for review see (Perry and Hodges 1999)). Other studies also suggest that the risk of converting to dementia is increased when multiple domains are impaired, including executive function (Albert et al. 2001; Nordlund et al. 2011). If only memory is assessed over time, it would be difficult to observe differences between healthy controls and MCI patients. Thus, examining non-memory domains may be a powerful tool for differentiating normal, age-related decline from cognitive decline due to underlying neuropathology.

Numerous studies suggest that healthy aging is associated with brain changes in both gray and white matter and also declines in several cognitive domains, including working memory and attention (Buckner 2004; Hedden and Gabrieli 2004; Raz et al. 1997). Although progress has been made in the understanding of the relationship between changes in the brain and patterns of cognitive aging, the neuroanatomical basis of these age-related changes in cognition continues to be a topic of debate (Raz and Kennedy 2009; Salthouse 2011). It is possible that the lack of decline on non-memory cognitive factors over 3 years by the controls in the current study reflects the profile of healthier “successful” agers compared with more “typical” agers (Hsu and Jones 2012; Negash et al. 2011). Additional longitudinal studies using comprehensive neuropsychological batteries are needed to help identify which cognitive features are the best predictors of conversion to dementia versus healthy aging.

In addition, when comparing the rates of change of different cognitive factors within the MCI group, the latent growth models suggest that executive function/processing speed changed at a faster rate than memory in MCI patients. In contrast, there was no decline in executive function/processing speed in the healthy controls. This diagnostic group by domain interaction shows a significant difference in the magnitude of change between memory and executive function between MCI and healthy controls. This suggests that executive function may be a potentially more sensitive measure of cognitive decline due to underlying neuropathology and may be a useful tool to distinguish healthy aging and MCI. Future studies are needed to further test this hypothesis. In contrast, the trajectory of decline in language, visuospatial, and attention in MCI was similar to the decline in memory, while there was no change over time on visuospatial and attention factors relative to memory in healthy controls. These domains appear less helpful for distinguishing MCI patients and healthy controls. Finally, because memory declined in both groups, it may also be useful to control for the rate of memory change when examining decline in executive function in future studies.

The second-order latent growth models used in the current study were robust and addressed the theoretical question at hand. Other multivariate alternatives are also available (McArdle 1988; Salthouse and Ferrer-Caja 2003). For example, to bolster causal inferences, it is possible to estimate two-stage piecewise longitudinal growth models in which earlier growth in one process predicts future change in another process or developmental stage (Chou et al. 2004). In the present study, we sought to compare trajectories among cognitive factors but do not make any causal attributions. It is also feasible to expect that mean levels and rates of decline in each cognitive domain do not describe trajectories of all participants equally well, and that there are subgroups of participants who decline faster or slower, depending on where they are in the pathological cascade of Alzheimer disease; such groups might be teased apart through growth mixture modeling (Leoutsakos et al. 2012). In yet another variation of longitudinal structural equation modeling, a bivariate dual change score model might be used to explicitly explore whether change in one cognitive domain is associated with change in another domain (McArdle and Prindle 2008); such models require equally spaced visits, which we do not have in ADNI unless we exclude the 6-month visit. These and other research questions should be pursued in future research to extend our knowledge of domain-specific cognitive decline in older adults.

Several limitations of the present study are important to mention. First, because of the way the indicators in the current study are scaled, the factor scores are not generalizable to other samples. We strictly compared relative change in various domains between healthy controls and MCI patients in the ADNI sample. Second, the latent growth models in the present study accommodated linear change in cognitive factors, and the model fit statistics in this study suggested this assumption was adequate. However, it is possible that certain tests declined faster or slower than others within a domain, or even that change in some tests demonstrated quadratic change. We did not explore indicator-specific trajectories because our goal was to make inferences at the level of cognitive domains and not individual tests. It is also important to keep in mind that we did not exclude participants in either group that had a change in diagnosis (e.g., converted to dementia or reverted to normal). The ADNI study also focuses on prodromal stage of Alzheimer's disease, so the results do not generalize to the MCI stages of non-Alzheimer's disease dementias. In addition, the homogeneous racial composition, high educational level, and age composition of the participants in ADNI limit the generalizability to other community samples. As discussed above, the controls in the study may represent a group of healthier “successful” agers compared with more “typical” agers (Hsu and Jones 2012; Negash et al. 2011), which also limits the generalizability to other community samples.

In conclusion, latent growth modeling appears to be a useful tool for investigating longitudinal change in neuropsychological performance in both healthy older adults and persons with MCI. The results of the latent growth models suggest that cognitive decline differs between healthy aging and MCI. The latent growth models also suggest that executive function, in particular, declines at a faster rate than memory in MCI patients. The findings also underscore the importance of examining non-memory cognitive decline for potentially differentiating healthy aging and MCI. It is important to replicate these results in other large studies, particularly those with more ethnic diversity, and to determine how the latent factors might also help predict conversion to dementia or functional decline.


We gratefully acknowledge a conference grant from the National Institute on Aging (NIA) (R13 AG030995, PI: Mungas) that facilitated data analysis for this project.

Dr. Johnson was supported by NIA grant R01 AG022538 (PI: Johnson). Dr. Gross was supported by a National Institutes of Health Translational Research in Aging fellowship (T32AG023480-07) and NIA grant P01 AG031720 (PI: Inouye). Dr. McLaren was supported by NIA grants P01 AG036694 (PI: Sperling) and K23 AG027171 (PI: Atri). Dr. Pa was supported by NIA grant K01 AG034175 (PI: Pa). Dr. Park was supported by NIA grant R01 AG031252 (PI: Farias). Dr. Manly was supported by NIA grants R01 AG028786 (PI: Manly) and R01 AG037212 (PI: Mayeux).

Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: Abbott; Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Amorfix Life Sciences Ltd.; AstraZeneca; Bayer HealthCare; BioClinica, Inc.; Biogen Idec Inc.; Bristol-Myers Squibb Company; Eisai Inc.; Elan Pharmaceuticals Inc.; Eli Lilly and Company; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; GE Healthcare; Innogenetics, N.V.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Medpace, Inc.; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Servier; Synarc Inc.; and Takeda Pharmaceutical Company. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health ( The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of California, Los Angeles. This research was also supported by NIH grants P30 AG010129, K01 AG030514, and the Dana Foundation.

The contents do not represent the views of the Dept. of Veterans Affairs, the United States Government, or any other funding entities.


Data used in preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database ( As such, the investigators with the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in the analysis or writing of this report. A complete listing of ADNI investigators can be found at: http:/

Contributor Information

Julene K. Johnson, Institute for Health and Aging; Department of Social and Behavioral Sciences, University of California, San Francisco, San Francisco, CA, USA. Department of Neurology, University of California, San Francisco, CA, USA. Institute for Health and Aging, University of California, San Francisco, 3333 California St., Suite 340, San Francisco, CA 94118, USA ; ude.fscu@nosnhoj.eneluj.

Alden L. Gross, Institute for Aging Research, Harvard Medical School and Division of Gerontology, Beth Israel Deaconess Medical Center, Boston, MA, USA.

Judy Pa, Department of Neurology, University of California, San Francisco, CA, USA.

Donald G. McLaren, Geriatric Research Education and Clinical Center, ENRM Veterans Hospital, Boston, MA, USA. Department of Neurology, Massachusetts General Hospital, Boston, MA, USA. Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Boston, MA, USA. Harvard Medical School, Boston, MA, USA.

Lovingly Quitania Park, Alzheimer's Disease Center, Department of Neurology, University of California, Davis, Davis, CA, USA.

Jennifer J. Manly, Taub Institute for Research on Alzheimer's Disease and the Aging Brain; Department of Neurology, Columbia University Medical Center, New York, NY, USA.


  • Albert MS, Jones K, Savage CR, Berkman L, Seeman T, Blazer D, et al. Predictors of cognitive change in older persons: MacArthur studies of successful aging. Psychology and Aging. 1995;10(4):578–589. [PubMed]
  • Albert MS, Moss MB, Tanzi R, Jones K. Preclinical prediction of AD using neuropsychological tests. Journal of the International Neuropsychological Society. 2001;7(5):631–639. [PubMed]
  • Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association work-groups on diagnostic guidelines for Alzheimer's disease. Alzheimer's & Dementia. 2011;7(3):270–279. [PMC free article] [PubMed]
  • Bennett DA, Wilson RS, Schneider JA, Evans DA, Beckett LA, Aggarwal NT, et al. Natural history of mild cognitive impairment in older persons. Neurology. 2002;59(2):198–205. [PubMed]
  • Buckner RL. Memory and executive function in aging and AD: multiple factors that cause decline and reserve factors that compensate. Neuron. 2004;44(1):195–208. [PubMed]
  • Carter SF, Caine D, Burns A, Herholz K, Lambon Ralph MA. Staging of the cognitive decline in Alzheimer's disease: insights from a detailed neuropsychological investigation of mild cognitive impairment and mild Alzheimer's disease. International Journal of Geriatric Psychiatry. 2011 [PubMed]
  • Chou C-P, Yang D, Pentz MA, Hser Y-I. Piecewise growth curve modeling approach for longitudinal prevention study. Computational Statistics & Data Analysis. 2004;46(213–225)
  • Dowling NM, Hermann B, La Rue A, Sager MA. Latent structure and factorial invariance of a neuropsychological test battery for the study of preclinical Alzheimer's disease. Neuropsychology. 2010;24(6):742–756. [PMC free article] [PubMed]
  • Folstein MF, Folstein SE, McHugh PR. Mini-mental state. A practical method for grading the mental state of patients for the clinician. J Psychiat Res. 1975;12:189–198. [PubMed]
  • Garner WR, Hake HW, Eriksen CW. Operationism and the concept of perception. Psychological Review. 1956;63(3):149–159. [PubMed]
  • Gomar JJ, Bobes-Bascaran MT, Conejero-Goldberg C, Davies P, Goldberg TE. Utility of combinations of biomarkers, cognitive markers, and risk factors to predict conversion from mild cognitive impairment to Alzheimer disease in patients in the Alzheimer's disease neuroimaging initiative. Archives of General Psychiatry. 2011;68(9):961–969. [PubMed]
  • Goodglass H, Kaplan E. The assessment of aphasia and related disorders. Lea & Febiger; Philadelphia: 1983.
  • Hayden KM, Reed BR, Manly JJ, Tommet D, Pietrzak RH, Chelune GJ, et al. Cognitive decline in the elderly: an analysis of population heterogeneity. Age and Ageing. 2011;40(6):684–689. [PMC free article] [PubMed]
  • Hedden T, Gabrieli JD. Insights into the ageing mind: a view from cognitive neuroscience. Nature Reviews Neuroscience. 2004;5(2):87–96. [PubMed]
  • Hodges JR, Erzinclioglu S, Patterson K. Evolution of cognitive deficits and conversion to dementia in patients with mild cognitive impairment: a very-long-term follow-up study. Dementia and Geriatric Cognitive Disorders. 2006;21(5–6):380–391. [PubMed]
  • Hsu HC, Jones BL. Multiple Trajectories of Successful Aging of Older and Younger Cohorts. Gerontologist. 2012:1–14. [PubMed]
  • Hu L, Bentler PM. Cutoff criteria for fit indices in covariance structure analysis: conventional versus new alternatives. Structural Equation Modeling. 1999;6:1–55.
  • Kaplan E, Goodglass H, Wintraub S. The Boston Naming Test. 2nd ed. Lea and Febiger; Philadelphia: 1982.
  • Kramer JH, Nelson A, Johnson JK, Yaffe K, Glenn S, Rosen HJ, et al. Multiple cognitive deficits in amnestic mild cognitive impairment. Dementia and Geriatric Cognitive Disorders. 2006;22(4):306–311. [PMC free article] [PubMed]
  • Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics. 1982;38(4):963–974. [PubMed]
  • Leoutsakos JM, Muthen BO, Breitner JC, Lyketsos CG. Effects of non-steroidal anti-inflammatory drug treatments on cognitive decline vary by phase of pre-clinical Alzheimer disease: findings from the randomized controlled Alzheimer's Disease Anti-inflammatory Prevention Trial. International Journal of Geriatric Psychiatry. 2012;27(4):364–374. [PMC free article] [PubMed]
  • Manly JJ, Tang MX, Schupf N, Stern Y, Vonsattel JP, Mayeux R. Frequency and course of mild cognitive impairment in a multiethnic community. Annals of Neurology. 2008;63(4):494–506. [PMC free article] [PubMed]
  • Matsuda O, Saito M. Multiple cognitive deficits in patients during the mild cognitive impairment stage of Alzheimer's disease: how are cognitive domains other than episodic memory impaired? International Psychogeriatrics. 2009;21(5):970–976. [PubMed]
  • McArdle JJ. Latent variable growth within behavior genetic models. Behavior Genetics. 1986;16(1):163–200. [PubMed]
  • McArdle JJ. Dynamic but structural equation modeling of repeated measures data. In: Nesselroade JR, Cattell RB, editors. The handbook of multivariate experimental psychology. Vol. 2. Plenum Press; New York: 1988. pp. 561–614.
  • McArdle JJ, Prindle JJ. A latent change score analysis of a randomized clinical trial in reasoning training. Psychology and Aging. 2008;23(4):702–719. [PubMed]
  • Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules [see comments]. Neurology. 1993;43(11):2412–2414. [PubMed]
  • Morris JC, Heyman A, Mohs RC, Hughes JP, van Belle G, Fillenbaum G, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD), I: clinical and neuropsychological assessment of Alzheimer's disease. Neurology. 1989;39:1159–1165. [PubMed]
  • Morris JC, Storandt M, Miller JP, McKeel DW, Price JL, Rubin EH, et al. Mild cognitive impairment represents early-stage Alzheimer disease. Archives of Neurology. 2001;58:397–405. [PubMed]
  • Mungas D, Beckett L, Harvey D, Farias ST, Reed B, Carmichael O, et al. Heterogeneity of cognitive trajectories in diverse older persons. Psychology and Aging. 2010;25(3):606–619. [PMC free article] [PubMed]
  • Muthén BO. Latent variable modeling with longitudinal and multilevel data. In: Raftery A, editor. Sociological methodology. Blackwell Publishers; Boston: 1997. pp. 453–480.
  • Muthén BO, Curran PJ. General longitudinal modeling of individual differences in experimental designs: a latent variable framework for analysis and power estimation. Psychological Methods. 1997;2:371–402.
  • Muthén LK, Muthén BO. Mplus user's guide: Sixth Edition. Muthén & Muthén; Los Angeles, CA: 1998–2010.
  • Negash S, Smith GE, Pankratz S, Aakre J, Geda YE, Roberts RO, et al. Successful aging: definitions and prediction of longevity and conversion to mild cognitive impairment. The American Journal of Geriatric Psychiatry. 2011;19(6):581–588. [PubMed]
  • Nordlund A, Rolstad S, Gothlin M, Edman A, Hansen S, Wallin A. Cognitive profiles of incipient dementia in the Goteborg MCI study. Dementia and Geriatric Cognitive Disorders. 2011;30(5):403–410. [PubMed]
  • Perry RJ, Hodges JR. Attention and executive deficits in Alzheimer's disease. A critical review. Brain. 1999;122(Pt 3):383–404. [PubMed]
  • Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, et al. Current concepts in mild cognitive impairment. Archives of Neurology. 2001;58(12):1985–1992. [PubMed]
  • Petersen RC, Aisen PS, Beckett LA, Donohue MC, Gamst AC, Harvey DJ, et al. Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology. 2010;74(3):201–209. [PMC free article] [PubMed]
  • Raz N, Kennedy KM. A systems approach to the aging brain: Neuroanatomic changes, their modifiers, and cognitive correlates. In: Jagust W, D'Esposito M, editors. Imaging the aging brain. Oxford University Press; New York: 2009. pp. 43–70.
  • Raz N, Gunning FM, Head D, Dupuis JH, McQuain J, Briggs SD, et al. Selective aging of the human cerebral cortex observed in vivo: differential vulnerability of the prefrontal gray matter. Cerebral Cortex. 1997;7(3):268–282. [PubMed]
  • Reitan RM. Validity of the Trailmaking Test as an indication of organic brain damage. Perceptual and Motor Skills. 1958;8:271–276.
  • Rey A. L'Examen Clinique en Psychologie. Presses Universitaires de France; Paris: 1964.
  • Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. The American Journal of Psychiatry. 1984;141(11):1356–1364. [PubMed]
  • Salthouse TA. Neuroanatomical substrates of age-related cognitive decline. Psychological Bulletin. 2011;137(5):753–784. [PMC free article] [PubMed]
  • Salthouse TA, Ferrer-Caja E. What needs to be explained to account for age-related effects on multiple cognitive variables? Psychology and Aging. 2003;18(1):91–110. [PubMed]
  • Steiger JH. EZPATH: A supplementary module for SYSTAT and SYGRAPH. Systat; Evanston: 1989.
  • Stoel RD, van Den Wittenboer G, Hox J. Analyzing longitudinal data using multilevel regression and latent growth curve analysis. Metodologia de las Ciencias del Comportamiento. 2003;5:1–21.
  • Strauss ME, Thompson P, Adams NL, Redline S, Burant C. Evaluation of a model of attention with confirmatory factor analysis. Neuropsychology. 2000;14(2):201–208. [PubMed]
  • Twisk JWR. Applied longitudinal data analysis for epidemiology: A practical guide. Cambridge University Press; New York: 2003.
  • Wechsler DA. Wechsler adult intelligence scale - revised. Psychological Corporation; New York: 1981.
  • Wechsler DA. Wechsler adult intelligence scale - revised. Psychological Corporation; New York: 1987a.
  • Wechsler DA. Wechsler memory scale - revised. Psychological Corporation; San Antonio: 1987b.
  • Weiner MW, Aisen PS, Jack CR, Jr., Jagust WJ, Trojanowski JQ, Shaw L, et al. The Alzheimer's disease neuroimaging initiative: progress report and future plans. Alzheimer's & Dementia. 2011;6(3):202–211. e207. [PMC free article] [PubMed]
  • Wilson RS, Beckett LA, Barnes LL, Schneider JA, Bach J, Evans DA, et al. Individual differences in rates of change in cognitive abilities of older persons. Psychology and Aging. 2002;17(2):179–193. [PubMed]
  • Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund LO, et al. Mild cognitive impairment–beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. Journal of Internal Medicine. 2004;256(3):240–246. [PubMed]